Category: Wesana Health Holdings

TORONTO and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of renowned psychedelics researcher, psychologist, and writer, James Fadiman, PhD, to its Scientific Advisory Board. In this role, Dr. Fadiman will provide strategic guidance and direction to Wesana’s scientific research efforts related to psychedelic-assisted psychotherapy to treat traumatic brain injury (TBI).

Called “America’s wisest and most respected authority on psychedelics and their use” Dr. Fadiman is a pioneer of psychedelics research who has played a seminal role in the study of psychology and psychedelics for over 50 years. Dr. Fadiman’s body of work underlies the current study and understanding of psychedelic medicines, including identification of guidelines for employing them safely and effectively across a range of applications.

On his appointment, Dr. Fadiman said, “The opportunity to realize the promise that these medicines represent is, after many years, finally coming to fruition. It’s very important me to ensure that the research on psychedelics is applied in the most effective way. I am very pleased to be joining Wesana’s scientific board in order to apply my knowledge to help those suffering from traumatic brain injury, migraine and related conditions, as well as to support Wesana’s long term innovation for improving neurological health.”

“Jim quite literally built much of the foundation on which nearly all of the current psychedelics research and understanding has been based. His knowledge and appreciation of the therapeutic value of psychedelic treatment is unmatched and his years of experience will provide invaluable guidance as we develop treatments for traumatic brain injury and other neurological ailments,” said Daniel Carcillo, co-founder and CEO of Wesana Health.

“Wesana’s Scientific Advisory Board will ensure that the extensive research we are performing will stand up under the highest level of scrutiny from the scientific community and ensure that we are operating at a level unmatched in the growing psychedelics industry. Dr. Fadiman will play an important leadership role as we continue to execute on our strategic research goals,” added Chad Bronstein, co-founder and Executive Chairman.

James Fadiman earned his BA from Harvard and his PhD from Stanford and has held a variety of teaching, consulting, training, counseling and editorial positions. He has served on a number of for profit and non-profit companies and has taught in psychology departments, as well as in design engineering. He has published textbooks, professional books, a self-help book, a novel, and a series of videos, Drugs: the children are choosing, for National Public Television. He has been involved in psychedelic research for more than fifty years, the last ten years uncovering and researching microdosing.

About Wesana
Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to future partnerships, collaborative research and the focus of the Company’s business. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance regarding the participation in, or success of, partnerships or collaborative research or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company’s profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: WesanaIR@kcsa.com
Phone: 212-896-1267

Media Contact:
Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972

 

Source: Wesana Health

Released May 27, 2021

TORONTO and CHICAGO, May 21, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data-driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the expansion of its executive leadership team with the hire of Mark Wingertzahn, PhD, as Chief Scientific Officer. In this role, Dr. Wingertzahn will be responsible for leading Wesana’s scientific research and drug development, as well as tactical implementation of Wesana’s nonclinical programs and regulatory strategy.

In his previous roles, Dr. Wingertzahn led Global Clinical Development, Toxicology, Preclinical Medicine and Drug Safety teams for drug development and approval in every major worldwide market. He led the Medical and Scientific Affairs and Clinical Development teams at both GSK and Pfizer and successfully gained regulatory approval for five first-in-class products across three first-in-class indications. Dr. Wingertzahn is an Instructor of Pediatrics at NYU (Medicine) and Associate Professor of Life Sciences & Allied Health at the NY Institute of Technology College of Osteopathic Medicine.

“Mark’s unparalleled expertise in drug and scientific development will be a critical component in driving Wesana’s clinical programs. His leadership as Chief Scientific Officer will ensure that Wesana is positioned to advance these treatments in development and more quickly meet the needs of the many people who suffering from TBI and related conditions,” said Daniel Carcillo, co-founder and CEO of Wesana Health.

“As head of Wesana’s Research Leadership Team, Mark brings exceptional leadership experience from a drug development background on a truly global scale. He will play an important part in continuing to execute on our strategic plan through the creation and execution of a best-in-class clinical trial and drug development program,” added Chad Bronstein, co-founder and Executive Chairman.

About Wesana
Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com.

Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Company’s ability to advance psychedelic medicines, including development of evidence-based formulations and protocols, its ability to implement clinical and nonclinical programs and the focus of the Company’s business. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance regarding the Company’s ability to advance psychedelic medicines, including development of evidence-based formulations and protocols, its ability to implement clinical and nonclinical programs or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company’s profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: WesanaIR@kcsa.com
Phone: 212-896-1267

Media Contact:
Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972

 

Source: Wesana Health

Released May 21, 2021

TORONTO and CHICAGO, May 10, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), formerly Debut Diamonds Inc., is pleased to announce that its shares will commence trading on the Canadian Securities Exchange (“CSE”) today, Monday, May 10, 2021 under the ticker symbol “WESA.”

“Following the completion of our go public transaction, we’re thrilled to embark on this journey as a public company listing on the CSE. As a CSE listed company, we will be able to increase engagement with our shareholders and the investment community as we continue to execute on our mission to develop alternative treatment solutions for traumatic brain injury,” said Daniel Carcillo, CEO of Wesana Health.

About Wesana Health
Wesana Health is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to trading on the CSE and the focus of the Company’s business. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the listing and trading of the Company’s shares on the CSE will occur or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company’s profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: WesanaIR@kcsa.com
Phone: 212-896-1267

Media Contact:
Nick Opich / Brittany Tibaldi
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 347-487-6794

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer

 

Source: Wesana Health

Released May 10, 2021

Shares Expected to Commence Trading on the CSE Under Symbol “WESA” on or about May 10, 2021

TORONTO and CHICAGO, May 06, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), formerly Debut Diamonds Inc. (CSE:DDI), announces the successful closing of its previously announced reverse takeover (“RTO”) of Debut Diamonds Inc. (“Debut”) by Wesana Health Inc.

In connection with the RTO transaction, a wholly-owned subsidiary of Debut merged with and into Wesana Health Inc., and all of the outstanding shares of Wesana Health Inc. were exchanged for shares of Debut, and Debut continued into the Province of British Columbia, changed its name to “Wesana Health Holdings Inc.”, consolidated its outstanding common shares on an approximately 28 for 1 basis and redesignated such shares as subordinate voting shares (the “Subordinate Voting Shares”). The Company now focuses on the business of Wesana Health Inc., which includes psilocybin-based medicine development and research that targets traumatic brain injury and other mental health ailments caused by trauma.

As previously announced, Wesana Health Inc. closed C$16.1 million in an oversubscribed private placement of subscription receipts through a special purpose financing vehicle ahead of the RTO. The round included existing investors Ambria Capital, LLC, as well as new investors JLS Fund, K2 & Associates, Sol Global, and George Steinbrenner IV. In connection with the RTO transaction, such subscription receipts were indirectly exchanged for Subordinate Voting Shares and warrants of the Company.

Commencement of Trading

On April 28, 2021, the Company received the conditional approval from the Canadian Securities Exchange (“CSE”) for the listing of the Subordinate Voting Shares that resulted from the closing of the RTO. The Company expects to commence trading on the CSE on or about Monday, May 10, 2021 under the symbol “WESA.”

The Company currently has 12,578,997 outstanding Subordinate Voting Shares, 134,418 outstanding super voting shares of the Company (“Super Voting Shares”) convertible into 6,720,900 additional Subordinate Voting Shares and 133,034 outstanding multiple voting shares of the Company (“Multiple Voting Shares”) convertible into 6,651,700 additional Subordinate Voting Shares.

New Board and Management

Following the RTO, the leadership team of the Company is as follows:

• Daniel Carcillo — Chief Executive Officer and Director
• Zed Wang – Chief Financial Officer
• Mark Wingertzahn, PhD — Chief Scientific Officer
• Dawn McCollough —Chief Operating Officer
• Stephan Bart, MD CPI — Chief Medical Officer
• Israel Mirsky — Chief Strategy Officer
• Chad Bronstein — Executive Chairman
• Mitch Kahn — Director
• Robert Koffman – Director
• George Michael Steinbrenner IV — Director

Additional information related to the Company’s business, capitalization and the RTO (including the members of the management team and board of directors listed above) will be available in the Company’s listing statement (the “Listing Statement”), which will be filed under the Company’s profile on SEDAR at www.sedar.com prior to the commencement of trading.

Early Warning Disclosure

Daniel Carcillo of Chicago, Illinois, the Chief Executive Officer of the Company, will file an early warning report in accordance with National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues related to the acquisition of 134,418 Super Voting Shares in connection with the closing of the RTO (the “Closing”).

Immediately prior to the Closing, Mr. Carcillo did not, directly or indirectly, hold any shares of the Company. Immediately following the Closing, he holds, directly, an aggregate of 134,418 Super Voting Shares (representing 100% of the issued and outstanding Super Voting Shares and, if converted into Subordinate Voting Shares, assuming the conversion of all Super Voting Shares and Multiple Voting Shares, 25.9% of then outstanding Subordinate Voting Shares). The shares held by Mr. Carcillo are for investment purposes, and are subject to an escrow time based release schedule, as more particularly described in the Listing Statement. Mr. Carcillo currently has no plans or intentions that relate to, or would result in, any of the actions requiring disclosure under the early warning reporting provisions of applicable securities laws. In accordance with applicable securities laws, Mr. Carcillo may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments of the Company in the open market or otherwise, and reserves the right to dispose of any or all of such securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to such securities, the whole depending on market conditions, the business and prospects of the Company and other relevant factors, subject to applicable escrow restrictions. A copy of the early warning report will be filed by Mr. Carcillo under the Company’s profile on SEDAR at www.sedar.com or may be obtained by contacting Allison Soss at 212-896-1267.

Chad Bronstein of Chicago, Illinois, the Executive Chairman of the Company, will file an early warning report in accordance with National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues related to the acquisition of 39,000 Multiple Voting Shares in connection with the Closing.

Immediately prior to the Closing, Mr. Bronstein did not, directly or indirectly, hold any shares of the Company. Immediately following the Closing, he holds or controls, directly and indirectly, an aggregate of 39,000 Multiple Voting Shares (representing 29.3% of the issued and outstanding Multiple Voting Shares and, if converted into Subordinate Voting Shares, assuming the conversion of all Super Voting Shares and Multiple Voting Shares, 7.5% of then outstanding Subordinate Voting Shares). Mr. Bronstein owns or controls 37,700 Multiple Voting Shares held by an associated holding company, SRB Ventures LLC, as well as 1,300 Multiple Voting Shares held by his wholly-owned holding company, CTB Capital LLC. The shares held or controlled by Mr. Bronstein are for investment purposes and are subject to an escrow time based release schedule, as more particularly described in the Listing Statement. Mr. Bronstein currently has no plans or intentions that relate to, or would result in, any of the actions requiring disclosure under the early warning reporting provisions of applicable securities laws. In accordance with applicable securities laws, Mr. Bronstein may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments of the Company in the open market or otherwise, and reserves the right to dispose of any or all of such securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to such securities, the whole depending on market conditions, the business and prospects of the Company and other relevant factors, subject to applicable escrow restrictions. A copy of the early warning report will be filed by Mr. Bronstein under the Company’s profile on SEDAR at www.sedar.com or may be obtained by contacting Allison Soss at 212-896-1267.

About Wesana Health
Wesana Health is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: WesanaIR@kcsa.com
Phone: 212-896-1267

Media Contact:
Nick Opich / Brittany Tibaldi
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 347-487-6794

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer

Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the proposed listing on the CSE, the focus of the Company’s business, and intentions of those subject to early warning disclosure requirements. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the expected listing and trading on the CSE, Wesana’s strategic plans and the intentions of those subject to early warning disclosure requirements are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the listing and trading of the Company’s shares on the CSE will occur or that, if they do occur, they will be completed on the terms and timing described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement for information as to the risks and other factors which may effect the Company’s business objectives and strategic plans.

 

Source: Wesana Health

Released May 6, 2021

TORONTO and CHICAGO, April 28, 2021 (GLOBE NEWSWIRE) — Wesana Health Inc. (“Wesana”) and Debut Diamonds Inc. (“Debut”) (CSE: DDI), today announced that they have obtained conditional approval from the Canadian Securities Exchange (“CSE”) for the listing of the subordinate voting shares that will result from the previously announced reverse takeover (“RTO”) of Debut by Wesana.

In connection with the RTO transaction, Wesana will amalgamate with a wholly-owned subsidiary of Debut, all of the outstanding shares of Wesana will be exchanged for shares of Debut, and Debut will change its name to “Wesana Health Holdings Inc.”

Final approval from the CSE is subject to Wesana and Debut meeting certain conditions required by the CSE, which includes completion of the RTO transaction. Upon receipt of the final approval, it is expected that Wesana Health Holdings Inc. will commence trading of its shares on the CSE under the ticker symbol “WESA.”

About Wesana Health
Wesana Health is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

About Debut Diamonds Inc.
Debut Diamonds Inc. is a mineral exploration company with no current activities or operations.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: WesanaIR@kcsa.com
Phone: 212-896-1267

Media Contact:
Nick Opich / Brittany Tibaldi
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 347-487-6794

Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the proposal to complete the RTO, listing on the CSE and associated transactions. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the expected terms of the RTO, Wesana’s strategic plans and the parties’ ability to satisfy closing conditions and receive necessary approvals in order to complete the RTO and associated transactions are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the RTO transaction will occur or that, if they do occur, they will be completed on the terms described above. Debut and Wesana assume no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.

 

Source: Wesana Health

Released April 28, 2021

CHICAGO, April 27, 2021 (GLOBE NEWSWIRE) — Wesana Health Inc. (“Wesana” or the “Company”), an emerging life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psilocybin-based medicine, today announced that Israel Mirsky has been appointed Chief Strategy Officer.

“I am deeply passionate about Wesana’s vision for the future of brain health, and the broad positive impacts more effective therapies in this area could have,” said Mr. Mirsky. “I am eager to develop initiatives and insight that help achieve Wesana’s goals and to continue building critical relationships for the company. Wesana has made tremendous progress already and I’m thrilled to join at this pivotal moment.”

Israel Mirsky is a cross-disciplinary technologist with a focus on anticipating and adjusting to the behavioral, cultural and ethical implications of rapid change. Most recently, Israel led global technology and emerging platforms at OMD, Adweek’s Global Media Agency of the Year for 2019 and 2020 and the world’s largest media network. There he was responsible for empowering teams around the world to deliver better business decisions, faster for many of the Fortune 500, including SCJ, SAP, Disney and many others, as well as for future proofing client business, thought leadership and technology product development.

Previously, he led the global Intel business for OMD, headed performance and social products for Omnicom’s marketing technology unit Annalect, and built out the emerging media and technology practice and cross-channel analytics teams for global PR firm Porter Novelli. In earlier roles, he has worked in artificial intelligence for programmatic marketing and in media technology consulting, leveraging his background in computer science.

“Israel’s expertise as a global strategic innovator will help make Wesana a leader in helping those who are currently facing neurological challenges including Traumatic Brain Injury,” said Daniel Carcillo, CEO of Wesana Health. “He has a track record of uncovering business critical insights and developing initiatives that translate into outstanding business results.”

About Wesana Health

Wesana Health is an emerging life sciences company championing the development of innovative approaches for better understanding, protecting and improving neurological health and performance. Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols, including psilocybin-based therapies, that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com.

On February 2, 2021, Wesana Health entered into a definitive agreement with Debut Diamonds Inc. (“Debut”) (CSE: DDI) to complete a business combination by way of a transaction (the “Transaction”) that will constitute a reverse takeover of Debut by Wesana Health. Upon closing of the transaction, Debut will change its name to Wesana Health Holdings Inc. and all of its directors and executive officers will resign and the board of directors and executive officers of Wesana Health Holdings Inc. will be comprised of the nominees of Wesana Health. Closing of the Transaction remains subject to satisfying various customary conditions precedent, including receipt of applicable regulatory and shareholder approvals.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: WesanaIR@kcsa.com
Phone: 212-896-1267

Media Contact:
Nick Opich
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206

Fallon Carter
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206

 

Source: Wesana Health

Released April 27, 2021